Circulating thrombospondin 2 as a predictor of hepatocellular carcinoma in hepatitis B patients undergoing nucleos(t)ide analog therapy
Scientific Reports · 2024
DOI: 10.1038/s41598-024-76532-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Taiki Okumura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621,…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Thrombospondins, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the joint research program of the Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Thrombospondin 2 (TSP2) plays a vital role in collagen/fibrin formation, bone growth, vascular density regulation, hemostasis, and cell adhesion. Close associations of serum TSP2 with histological severity in non-alcoholic fatty liver disease and chronic hepatitis C were reported. The present study investigated the significance of circulating TSP2 in chronic hepatitis B patients. Eighty-seven biopsy-proven chronic hepatitis B patients were analyzed in cross-sectional Study 1 to search for correlations between serum TSP2 levels prior to liver biopsy and clinicopathological parameters. In longitudinal Study 2, 51 chronic hepatitis B patients with long-term follow-up (mean: 7.5 years) were examined for changes in serum TSP2 levels during nucleos(t)ide analog (NA) therapy along with trends in hepatocarciongenesis. In Study 1, serum TSP2 levels were not significantly associated with portal inflammation or fibrosis. Study 2 revealed that serum TSP2 was significantly decreased after 48 weeks of NA therapy (P < 0.001). Notably, TSP2 levels at 48 weeks of NA administration (TSP2-48W) were significantly higher in the hepatocellular carcinoma (HCC) (+) group than in the HCC (-) group (P = 0.043). Kaplan-Meier analysis showed that higher TSP2-48W (≥ 24 ng/mL) was associated with future HCC development (P = 0.030). Serum TSP2 levels may be a potential predictor of HCC development in hepatitis B patients receiving NA therapy. Longitudinal prospective studies are necessary to validate our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
- Department of Advanced Endoscopic Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
- Division of Gastroenterology and Hepatology, Department of Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. kimuratakefumii@yahoo.co.jp.
- Consultation Center for Liver Diseases, Shinshu University Hospital, Matsumoto, Japan. kimuratakefumii@yahoo.co.jp.
- Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
- Department of Health Promotion Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Förderung
- the joint research program of the Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Okumura, T., Kimura, T., Ichikawa, Y., Iwadare, T., Wakabayashi, S. I., Kobayashi, H., Yamashita, Y., Uchida, T., Pydi, S. P., Tanaka, N., & Umemura, T. (2024). Circulating thrombospondin 2 as a predictor of hepatocellular carcinoma in hepatitis B patients undergoing nucleos(t)ide analog therapy. Scientific Reports. https://doi.org/10.1038/s41598-024-76532-5
Vancouver
Okumura T, Kimura T, Ichikawa Y, Iwadare T, Wakabayashi SI, Kobayashi H, et al. Circulating thrombospondin 2 as a predictor of hepatocellular carcinoma in hepatitis B patients undergoing nucleos(t)ide analog therapy. Scientific Reports. 2024. doi:10.1038/s41598-024-76532-5
BibTeX
@article{Okumura2024,
author = {Okumura, Taiki and Kimura, Takefumi and Ichikawa, Yuki and Iwadare, Takanobu and Wakabayashi, Shun-Ichi and Kobayashi, Hiroyuki and Yamashita, Yuki and Uchida, Takuro and Pydi, Sai P and Tanaka, Naoki and Umemura, Takeji},
title = {Circulating thrombospondin 2 as a predictor of hepatocellular carcinoma in hepatitis B patients undergoing nucleos(t)ide analog therapy},
journal = {Scientific Reports},
year = {2024},
doi = {10.1038/s41598-024-76532-5}
}
EUVIMED